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Introduction
Severe sepsis is a systemic host response to invading
pathogen with activated inflammation, coagulation and
tissue remodelling cascades and consequent organ dys-
function. Despite modern intensive care, mortality in
severe sepsis remains high. Mesenchymal stromal cells
(MSCs) are known to have many anti-inflammatory
features and contribute to the healing process. Many
research groups have demonstrated good results using
MSCs as an adjunctive treatment of sepsis in animal
studies. Recently, a research group conducted a phase I
clinical trial to test safety of MSCs on ARDS patients
([1]). To date knowledge of sepsis influence on MSCs is
scarce.
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Figure 1 A. PINP concentration in FBS and human groups. B. PIIINP concentration in human groups. C. PIIINP/PINP ratio in human
groups. *** = p < 0.001. * = p < 0.05.
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Objectives
Our aim was to study the capability of MSCs to produce
extracellular matrix components, type 1 and 3 collagens,
when exposed to serum of septic patients in an experi-
mental in vitro sepsis model.
Methods
Bone marrow MSCs (BM-MSC) were exposed to four
different cell culture conditions: 1. Standard BM-MSC
cell culture media (SCCM) with 20 % FBS, 2. SCCM
with 20 % FBS added with 3 ng/ml TNF-alpha, 3.
SCCM with 20 % human serum pooled from healthy
volunteers (serum n = 8), 4. SCCM with 20 % human
serum pooled from patients diagnosed with septic shock
(serum n = 6). BM-MSCs were incubated for four days
and the supernatant were collected and stored in -70° C
until analysis. Production of type 1 and 3 collagens were
determined by measuring the concentration of type 1
and 3 collagens N-terminal propeptide (PINP and
PIIINP) from cell culture media. PINP concentration
was determined with a chemiluminescence immunoas-
say (IDS iSYS, Immunodiagnostics Systems, Boldon,
UK) and PIIINP concentration was determined with a
radioimmunoassay (Orion Diagnostica, Espoo, Finland).
Results
In all BM-MSC lines, and repeated experiments (n = 6),
production of both PINP and PIIINP were suppressed
in the sepsis group (p < 0.001 both PINP and PIIINP).
Addition of TNF-alpha, 3 ng/ml did not have effect on
PINP levels in FBS groups. PIIINP/PINP ratio increased
significantly in sepsis group compared to control group
(p < 0.05) (Figure 1). Data is presented as mean ± SD.
Conclusions
Serum from patients with severe sepsis suppresses the
MSCs capability to produce collagen I and III in vitro.
The PIIINP/PINP profile is also altered in favour of
PIIINP over PINP. These results suggest that septic
environment alters the extracellular matrix remodelling
capability of MSCs, which in turn can alter tissue heal-
ing in vivo. This should be taken into consideration
when using MSC therapy in severe sepsis.
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